Image source: The Motley Fool.
Leidos Holdings Inc (LDOS 0.93%)
Q3Â 2020 Earnings Call
Nov 2, 2020, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Greetings. Welcome to the Leidos Third Quarter 2020 Earnings Call. [Operator Instructions] Please note this conference is being recorded.
At this time, I'll turn the floor over to Peter Berl with Investor Relations. Please go ahead.
Peter M. Berl -- Head of Investor Relations
Great. Thank you, Rob, and good morning, everyone. I'd like to welcome you to our third quarter 2020 earnings conference call. Joining me today are Roger Krone, our Chairman and CEO; Jim Reagan, our Chief Financial Officer; and other members of the Leidos management team.
Today, we will discuss our results for the quarter ending October 2, 2020. Roger will lead off the call with notable highlights from the quarter, as well as comments on the market environment and our Company's strategy. Jim will follow with a discussion of our financial performance and our guidance expectations. After these remarks from Roger and Jim, we'll open the call for your questions.
Today's discussion contains forward-looking statements based on the environment as we currently see it, and as such, does include risks and uncertainties. Please refer to our press release for more information on the specific risk factors that could cause actual results to differ materially.
Finally, during the call, we will discuss GAAP and non-GAAP financial measures. A reconciliation between the two is included in the press release that we issued this morning and is also available in the presentation slides. The press release and presentation, as well as a supplementary financial information file are provided on the Investor Relations section of our website at ir.leidos.com.
With that, I'll turn the call over to Roger Krone.
Roger Krone -- Chairman and Chief Executive Officer
Thank you, Peter, and thank you all for joining us this morning for our third quarter 2020 earnings conference call. As we near the end of a challenging year, from both an individual and community perspective, I sincerely hope that each of you and your loved ones remain safe and healthy.
Leidos' third quarter results reflect the hard work and dedication of our employees and close collaboration with our customers as we provided continuity of operations while accelerating our pandemic response plans. This is evidenced by record revenue, solid margins, record backlog and record operational cash generation. While challenges still remain, we're pleased with the growth and margin trajectory as we enter the fourth quarter and beyond.
In the quarter, the business delivered revenue of $3.24 billion, a new high watermark for the corporation, reflecting 14.4% growth from the prior year. Adjusting for acquisitions and divestiture activity, organic revenue grew by almost 2%, demonstrating the declining effects of COVID-19 as our teams diligently executed their recovery plans.
We recorded non-GAAP fully diluted earnings per share of $1.47, up 8% from the prior year. In addition, the business generated a record $592 million of cash from operations.
Net bookings of $4.3 billion in the quarter, year-to-date book-to-bill of 1.3 times, as well as 1.5 times on a trailing 12-month basis, despite several bid protests at the end of the quarter.
Adjusted EBITDA margins of 10.7% reflect strong program execution across all business segments, including an accelerated reopening of our medical exam business as we designed work flow protocols and safety measures that met customer requirements. While the impact of maintaining our fixed cost exam infrastructure was deeply felt in Q2, that investment was the right decision as the market demand for our services rebounded well in the third quarter as demonstrated by our results.
For the quarter, COVID-19 impacts to the overall business were approximately $109 million in revenue and $23 million in operating income, representing a significant decline from the prior quarter's impact of $223 million and $78 million, respectively. Furthermore, third quarter impacts were partially offset by program performance and on-contract growth across our highly diversified portfolio. We continue to expect recovery of greater than 70% of COVID-19 impacts in future quarters.
Now, turning to some notable awards that contributed to our ninth consecutive quarter of record backlog. In the Defense Solutions segment, Leidos was awarded a $306 million follow-on contract by the Army Contracting Command to provide the full spectrum of turnkey ground and flight operations for the Saturn Arch Aircraft in OCONUS contingency environments. In the Civil segment, we won a $292 million prime contract by the Federal Aviation Administration to design and develop a system to provide real-time access to essential weather, aeronautical, and National Airspace System, NAS, information through a common NASwide Enterprise-Information Display System. Additionally, within the Intelligence Community, the Company was awarded contracts collectively valued at $445 million, which encompass mission-critical services that help to counter global threats and strengthen national security.
Our $31.7 billion backlog, about 2.5 times our third quarter annualized revenue run rate, coupled with our strong new business pipeline provides a strong foundation for accelerated growth into next year and beyond. Furthermore, our backlog does not reflect recent awards with the Defense Health Agency and the Army Special Operations Command due to protest activity at the close of the quarter. Similarly, the $8 billion Navy NextGen protest remains in the US Court of Federal Claims with oral arguments now scheduled for November 13. We still anticipate a favorable outcome shortly thereafter.
Now, turning to the macro environment. The US government is currently operating under a continuing resolution through December 11, which includes an extension of Section 3610 of the CARES Act. It is likely that the CR is extended into the next calendar year. We do not anticipate any material impacts to our 2020 year-end results. Furthermore, we remain engaged with our industry partners to help ensure that extension of the CR, also includes the existing Section 3610 language.
Looking to 2021 and beyond, we continue to have conviction that our positioning in infrastructure, space exploration and healthcare in the federal, civil markets and in unmanned systems, hypersonics and digital modernization, in the defense and intel markets, closely aligns with our customers' enduring needs, which are supported by both sides of the aisle within the Federal Government.
Next, I want to update you on the Leidos Relief Foundation, which has been a tremendous resource for so many members of Leidos family who have been affected by the pandemic. The Foundation is generously funded by hundreds of fellow employees, as well as members of the Leidos executive leadership team and Board of Directors. To date, funds from the Foundation have already been directed to assist 175 employees or employee families who have experienced a financial hardship or lost a loved one during these challenging times. The health and well-being of our employees is our top priority, and I am proud to be part of a team that continually supports one another.
I want to mention one other important development to you today. On October 20, we announced the departure of a valued colleague from our Board of Directors, Lawrence C. Nussdorf. Larry stepped down from the Company's Board of Directors for medical reasons, effective October 15. Larry has dedicated more than a decade of service and leadership to our Company, seeing us through transformational change growth and helping create enviable shareholder value. He has accelerated our strategies and added value at every turn.
Recognizing that Larry is irreplaceable, our Board decided to eliminate the vacancy caused by his departure, and we will carry on with 12 Directors. To say that we will miss Larry is an understatement, as his expertise in all aspects of financial investment and legal activities gave us a sounding Board we could always rely on. I am personally thankful for his friendship and counsel. At times, he has challenged me and I have grown because of it. I am incredibly appreciative of his mentorship and friendship, and I didn't want to close today without acknowledging his many contributions. We wish Larry and his family well, as he focuses on his recovery.
I will now turn the call over to Jim Reagan, our Chief Financial Officer for more details on our third quarter results and guidance.
James Reagan -- Chief Financial Officer
Thanks, Roger, and thanks to everyone for joining us on the call today. In the interest of getting to your questions, I'll focus my comments on our solid third quarter results and full-year guidance.
Third quarter revenue was strong, growing 14% over the prior year period, including 1.7% organically. In addition to contributions from recent acquisitions, our growth was primarily fueled by recent program wins and on-contract growth, plus our ability to accelerate the reopening of medical exam clinics, which is a part of our business with high operating leverage. Today, we are performing at volumes that exceed pre-pandemic levels to address the backlog of medical exams that had built up during the second quarter. These increases were partially offset by $109 million of COVID-19 impacts, comprised of approximately $40 million of year-over-year impacts, plus $69 million of anticipated growth that we would have achieved on existing and new programs. Adjusting for the impact of COVID-19 on the quarter, organic revenue growth would have been roughly 5.5%.
Adjusted EBITDA margins were also strong at 10.7%, consistent with the prior year period in spite of a $23 million COVID-19 headwind to expected growth. This compares well with our prior year adjusted EBITDA margin of 10.7%, which had been assisted by the $54 million Greek arbitration award. Our robust margins this quarter were driven by exceptional program execution and indirect cost management across all of our segments.
Non-GAAP diluted EPS of $1.47 exceeded our expectations, growing $0.11 over the prior year period. Our strong program performance and increased volume on existing and new programs, partially offset by higher interest expense drove the 8% growth year-over-year.
Record high operating cash flows of $592 million for the quarter were driven by strong operational performance across the enterprise, higher customer advanced payments and favorable timing of vendor disbursements. The AR monetization facility contributed only $7 million during the quarter.
Keeping with our disciplined capital deployment strategy and our commitment to delever, this quarter we used cash on hand to pay down $477 million of debt, retiring a $450 million senior unsecured note three months early. Additionally, in October, we completed a $1 billion bond deal that benefited us in three ways: first, enabled by our investment-grade credit rating, we were able to capitalize on favorable market conditions by securing lower long-term interest rates; second, we replaced certain debt instruments with -- ones with extended maturities; and lastly, the deal provided our balance sheet with greater near-term liquidity that allows us to take advantage of smaller tuck-in acquisition opportunities, where speed of execution provides us with an advantage.
As of the end of the quarter, our adjusted net leverage was slightly above 3.0, which was a goal we had previously set for early 2021 after we completed the two acquisitions earlier this year. Having reached our target leverage, we remain committed to our long-term balanced capital deployment strategy, which consists of being appropriately levered and maintaining our investment-grade rating, returning a quarterly dividend to our shareholders and reinvesting for growth both organically and inorganically and returning excess cash to shareholders in a tax-efficient manner.
Bookings of $4.3 billion were strong across all segments and resulted in a 1.3 time book -- consolidated book-to-bill with record backlog, ending the quarter at $31.7 billion. This record backlog reflects a 33% increase over the prior year period. It's also worth noting that excluded from our book-to-bill and our backlog is the impact of $9 billion of contract awards that are currently under protest.
Now, for an overview of our segment results. Defense Solutions revenue increased 22% over the prior year and 3.5% organically. Driving this growth was the Dynetics acquisition and the strong execution of new programs, partially offset by COVID-19 impacts of $26 million from reduced volumes on legacy programs and $14 million from expected growth.
Non-GAAP operating margins in the Defense Solutions segment of 8.8%, grew 110 basis points from the prior year quarter. Contributing to the increase was the Dynetics acquisition, new program wins and reduced indirect spending, partially offset by impacts due to COVID-19, including the effects of maintaining mission-essential personnel in a ready state for key customers.
Defense Solutions booked over $1.8 billion in net awards, resulting in a book-to-bill of 0.9x for the quarter and 1.2x on a trailing 12-month basis.
In our Civil segment, revenue grew 5.2% over the prior year period and contracted 4.9% organically. The top line growth was driven by the acquisition of the security detection and automation businesses. This increase was offset by COVID-19 impacts, consisting of $14 million from reduced program volumes and $38 million from expected growth on existing and new programs.
Civil non-GAAP operating margins of 10.5% increased 220 basis points over the prior year quarter. The primary drivers were increased volumes on mature programs and a decrease in bad debt expense that reduced the prior year's third quarter results. Civil recorded nearly $1 billion in net bookings for the quarter, resulting in a 1.3 times book-to-bill and 2.4 times on a trailing 12-month basis.
And finally, turning to our Health segment. Health segment revenues increased 2.4% over the prior year quarter and 30% sequentially. Additionally, after adjusting for acquisition and divestiture activity, Health revenues grew 5.8% organically. This growth was directly attributable to the hard work accomplished by our team to both reopen and ramp the medical exam business back to pre-COVID levels faster than previously forecasted.
Health segment non-GAAP operating margins were strong at 16.3%, an increase of 150 basis points over the prior year quarter, reflecting the accelerated recovery in our medical exam business, the divestiture of the Health staff augmentation business in the third quarter of 2019 and a reduction in business investments.
The Health segment booked over $1.5 billion in net awards driven by an increase to backlog in the medical exam business based on sustained elevated case deliveries and demand. This 13% growth over the prior year period resulted in a 3.0 book-to-bill for the quarter and a 1.0 on a trailing 12-month basis.
Moving now to the remainder of the year. With the strength of our Q3 results, we are revising our 2020 guidance as follows. We expect revenue for the year to be between $12.3 billion and $12.5 billion, reaffirming the prior midpoint and tightening the range. This update reflects the execution of our strategy outlined in the second quarter earnings call, and returning to normalized run rates and business mix in the fourth quarter.
We expect adjusted EBITDA margins for the year between 10.6% and 10.8%, a 60 basis point increase at the midpoint from the previous guidance. This reflects the improved margins in the third quarter from high staff utilization, reduced indirect costs and strong program execution across the entire business.
We now expect non-GAAP diluted earnings per share between $5.65 to $5.85, an increase of $0.35 at the midpoint of the prior guide.
Finally, we expect cash from operations to be at at least $1.2 billion consistent with the prior guide. However, due to the strong cash flow generated on a year-to-date basis, coupled with the additional liquidity stemming from the October bond deal, we no longer anticipate any full-year contribution from our existing AR monetization facility, whereas the prior guidance had assumed $300 million.
As we look to the coming year, the accelerated recovery we have seen during the third quarter, along with our strong level of contract awards this year gives us increased confidence that we will have a strong 2021. Assuming continued success and defending the awards that are in protest and our customers continued ability to adapt to the pandemic, we could achieve organic revenue growth in 2021 of at least 10% to 12% and adjusted EBITDA margin of approximately 10.3% or better. As is our normal business practice, formal 2021 guidance will be discussed at our first -- our fourth quarter earnings conference call.
And with that, I'll turn the call over to Rob, so we can take some questions.
Questions and Answers:
Operator
Thank you. [Operator Instructions] Thank you. Our first question today comes from the line of Joseph DeNardi with Stifel. Please proceed with your questions.
Joseph DeNardi -- Stifel Financial Corp. -- Analyst
Thanks. Good morning.
Roger Krone -- Chairman and Chief Executive Officer
Hi. Good morning, Joe.
James Reagan -- Chief Financial Officer
Hey, Joe.
Joseph DeNardi -- Stifel Financial Corp. -- Analyst
Yeah. Good morning. Jim, can you maybe just provide some of the puts and takes that go into the margin commentary for next year that you just talked about? Maybe what are some of the headwinds? How much of that is tied to COVID versus newer opportunities ramping up? Thank you.
James Reagan -- Chief Financial Officer
Sure. For next year, Joe, we don't see a significant headwind related to COVID. And as we've said in the call, we're really finding ourselves within -- with a reduction in run rate in indirect expenses, strong program execution.
And in terms of how we're thinking about next year? I want to make sure I reiterate the fact that this is really preliminary. And it's based on where we see the numbers penciling out for next year, we're right in the middle of our planning process. And right now we're seeing some ability to sustain the strength in margins that we're seeing in the third quarter.
The only real headwinds that are worth pointing out right now that we have to be cognizant of is that, we have a couple of very large new programs ramping in the coming year. And as we've said before, typically margins on those programs can be as low as low-single digits. We think of our entire Company as a portfolio of programs, and while there are a number of programs that have margins that continue to increase, that we do have a couple of big programs where we have early stage margin pressure that typically starts to resolve itself after the first couple of years of these long-term programs. And that's really what that reflects. We feel like, given the portfolio that we have, we're definitely going to be seeing strengthening margins into next year.
Joseph DeNardi -- Stifel Financial Corp. -- Analyst
Okay. That's helpful. And then, Roger, I'm wondering you could just talk about kind of the overall award environment. Book-to-bill was maybe a little seasonally light. You're not alone, some of your peers have reported similar. But are you -- did you see any kind of slowdown in the quarter or do you see pent-up demand over the next few quarters? Thank you.
Roger Krone -- Chairman and Chief Executive Officer
Maybe a little. There is -- we have a program with the FAA that -- we say it's going to award any week and then we don't know which week. I think our book-to-bill was probably impacted more by protests. One of those program was -- is was the second protest. And we had sort of hoped that we had answered all the issues from the first protest. And we are optimistic that we would have booked that in the quarter and it turned out that didn't happen. And then Navy NextGen got delayed about another two weeks.
So, I just -- there is always some delays to the right, even in good times before COVID, it's -- there's -- within a given month, it's a little bit unpredictable and with the government's fiscal year there was stuff that was trying to get out within the quarter and it slid. We think we'll pick most of that up in fourth quarter and we haven't seen from the customer activity like an effect from, I don't know whether we call ourselves in a second wave or third wave or whatever you want to call, where we are now, but it certainly -- I don't see things accelerating. But I think they're kind of go into the usual pace. So, for us really the 1.3 times really is a protest story.
Thanks, Joe.
Joseph DeNardi -- Stifel Financial Corp. -- Analyst
Yeah. Thank you.
Operator
The next question is from the line of Seth Seifman with J.P. Morgan. Please proceed with your questions.
Seth Seifman -- J.P. Morgan -- Analyst
Hey. Thanks very much and good morning.
James Reagan -- Chief Financial Officer
Good morning, Seth.
Seth Seifman -- J.P. Morgan -- Analyst
I wonder in that --. Good morning. In that outlook for next year in terms of how you think about the duration of the continuing resolution and at what point it starts to have an impact, given that we could have an extended one following the election?
Roger Krone -- Chairman and Chief Executive Officer
Yeah. Our base assumption is that, we get another CR on December 11, it includes 3610, and frankly, it probably goes to March. We get through whatever happens tomorrow and that its effect on January and it's either the current administration and they have a lot of vacancies they want to fill or it's a new administration, and they've got vacancies. I think our assumption is, here, they are going to see are their way all the way through that until they fill out their leadership team. And so, it could be March. Could be even beyond that. And there is precedence for this. We've seen it before. So it's fully baked into our thoughts about the future, and that means, you'd be halfway through the government fiscal year before you actually get a bill.
But again, we've all been doing this a long time, we've seen it before. And frankly, there may even be an advantages because if we get a CR then everybody holds under the budgets that they had last year and you don't see a lot of reprioritization among different programs at different agencies. So, no, I don't see much impact.
Seth Seifman -- J.P. Morgan -- Analyst
Okay. Thanks. And then if I could just follow-up quickly on the two acquisitions and their contributions in the quarter, very nice sequential pickup on Dynetics. And just how things are tracking there versus your expectations for the year and into 2021? And then, slight sequential step down in the airport security products and kind of how things are shaping up there given what's happening in the air travel environment?
Roger Krone -- Chairman and Chief Executive Officer
Yeah. I'll do sort of the qualitative, and if Jim wants to put a little bit of quantitative out there, he can. But let me start from the active integrating. Okay? That's back office systems people. And the both Dynetics and the security detection and automation business are doing really quite well. I mean, we're ahead of our milestones. We're getting systems converted, people converted to our employee system. And so, that's going really, really well.
From a leadership standpoint, we're just really pleased and excited that the leadership team of both organizations have continued to stay and we're very happy that we've literally -- we lost nobody off of either senior leadership team.
The Dynetics business, because of Lander and some other things is ahead of our expectations and we integrated them with our Leidos Innovation Center and that has really created some cross-linking into our existing R&D business, which is really, really exciting.
I think you touched on what's going on in air traffic. We were over 1 million passengers like two weeks ago. And then this sort of second wave has tempered that a little bit. And so, we have seen -- we've got a couple foreign bids that have gotten delayed by a couple of weeks. TSA is actually move forward with some CT at the checkpoint opportunities, but our expectation is, it's going to be a long recovery, and orders are going to stretch to the right. And so, there was, I think a cause to have a balanced view of our security detection and automation business. But -- and by the way, for us, that's almost good because we get a chance to really focus on integration and get those systems and processes into what we call the Leidos business framework and where we want them before we see any significant ramp up. But the -- we've seen air traffic. I think the UK just went on a month shut down. And so, this second wave, third wave is going to be problematic. And I think we're very circumspect about that and its effect it will have on our business. But a great opportunity for us to get our CT product to the market and to get things through the qualification process with TSA. So, again, we're very excited about that business. It's just we're in the middle of this second wave in the pandemic.
Jim, I don't know if you want to talk about numbers?
James Reagan -- Chief Financial Officer
Just to amplify what you said Roger, the Dynetics business is performing in some metrics better than we expected on some we're spot on and we're pleased with how that business is accelerating through integration. And as you said, that's tempered with the other acquisition, which is seeing some of the COVID-19 impacts, not so much with win rates, but more how some awards and some deliveries have been pushed out as a result of the pandemic. Thanks.
Seth Seifman -- J.P. Morgan -- Analyst
Great. Thank you very much.
Roger Krone -- Chairman and Chief Executive Officer
You're welcome.
Operator
The next question is from the line of Matt Akers with Barclays. Please proceed with your questions.
Matthew Akers -- Barclays -- Analyst
Hey. Good morning, guys. Thanks for taking my question.
James Reagan -- Chief Financial Officer
Good morning, Matt.
Matthew Akers -- Barclays -- Analyst
I wanted to follow-up real quickly on the CR commentary and, if needed, the 3610 extension. I just wanted to ask kind of how important is that specifically? I think based on some of the commentary from some of your peers, I think it sounded like a lot of people covered by 3610 had already sort of returned to work. So if you could just comment on sort of how big that is for you at this point?
Roger Krone -- Chairman and Chief Executive Officer
Yeah. Well, I'm happy to share our numbers. So 97% of our team is back at work on regular hours. So, we have really only about 1.5% at a reduced standing and that's the people that would really be affected by 3610 and then we have a 1.5% is kind of miscellaneous just some structural things. And so, it's really not a big impact for us anymore. And I think that's -- we've seen that across the industry and certainly, our peers in these agencies.
I think it -- there are some things around 3610 that may be more important for some of the bigger aerospace primes relative to factories and things, but that doesn't affect many of our programs because of the nature of our work, which is really people come into work and writing software and doing mission and things like that. And so, not as important as it was at the beginning of this journey. Would still be nice to have. And -- but we don't see a major impact.
Matthew Akers -- Barclays -- Analyst
Okay. Thanks. That's helpful. And then, I guess, if I could just one more on sort of budget risk next year. I think that's kind of the biggest concern I see from investors. But, I guess, if you just sort of looked across your addressable market, are there certain areas that you think are may be more susceptible to the budget cut as you look out over the next couple of years as opposed to maybe other areas that you think are more well protected? And then how do you think about sort of positioning Leidos within that?
Roger Krone -- Chairman and Chief Executive Officer
Yeah. We've talked about it at the last quarter and I'll just reiterate some of our themes. If you're in support of legacy programs within DoD, I mean, that's probably not a great place to be. You want to be in the emerging technologies, I think, regardless of who gets elected. And the Biden campaign has come out and said, that they are not looking to cut defense. And we think that's true. That means they're not going to cut it. They probably wouldn't grow it as fast as a second Trump Administration would. And then the shifting of priorities. I think Biden is going to kind of go back to international alliances and maybe reopen trade. I think the Trump will continue what he has done.
We think in any administration, pandemic response, healthcare, civil infrastructure, we think our return to the moon program is strongly supported by the way from both sides of the aisle, both administrations have said that. And I've said this in many, many calls is, everybody gets elected or reelected with hopes and ambitions and a set of priorities. And then you walk in the office and you're faced with a record deficit, there is [Phonetic] 8%, 9% unemployment and you're on the precipice of a recession. And so, I think either administration is going to look for another CARES Relief Act. I think the tax increase, which is reported in the Biden Administration will be delayed because the last thing they want to do is tamp down economic growth because that's how we pull ourselves out of this large unemployment.
And so, I actually think that 2021 looks a lot like 2020 and 2022 is already in planning, it's in what we call the POM and EPP cycle, if you talk to customers, they've already put their budgets in for 2022. And, of course, our backlog takes us well into 2023 and 2024 before our program start to be affected.
And so, there will be changes in priorities, more civil infrastructure. I think we've got to get pandemic response ready and that CDC and organizations like FEMA and NIAID and USAID and NIH, all of which we have been carefully positioning the Company with a balanced portfolio to be able to address what would be a shifting priorities in the Federal Government. And so, we're very happy with where we're positioned and we're going to continue to stay up late tomorrow night and see who got elected. But I think we're going to be in great shape either way.
Matthew Akers -- Barclays -- Analyst
Great. Thank you.
James Reagan -- Chief Financial Officer
Yeah. Thanks, Matt.
Operator
Our next question is from the line of Sheila Kahyaoglu with Jefferies. Please proceed with your questions.
Sheila Kahyaoglu -- Jefferies LLC -- Analyst
Hi. Good morning, Roger and Jim.
Roger Krone -- Chairman and Chief Executive Officer
Hey. Good morning, Sheila.
Sheila Kahyaoglu -- Jefferies LLC -- Analyst
Roger, don't tell us 2021 is going to look like 2020. I don't think anybody wants that. So...
Roger Krone -- Chairman and Chief Executive Officer
Yeah. Great point. Absolutely great point.
Sheila Kahyaoglu -- Jefferies LLC -- Analyst
How do we -- I wanted to ask first on the revenue drivers in Defense and Civil. What's going on in those businesses? I appreciate the ex-COVID impact, they were up 6% and 2% organically. So what are some of the puts and takes and how do we think about those going forward?
Roger Krone -- Chairman and Chief Executive Officer
Hey, Sheila, before Jim answers that, I'll just comment, when the kids come around on Halloween dressed as a calendar named 2020, you know nobody wants to repeat what we did this year.
Sheila Kahyaoglu -- Jefferies LLC -- Analyst
Exactly.
James Reagan -- Chief Financial Officer
Yeah. So, in particular Defense and Civil revenue drivers, both for -- actually for the back end of this year and into next, some program wins that represented takeaways and growth in existing programs are really the drivers. And we had an Air Force takeaway, for example, I'll just give you a couple of examples something called ACC ISR, which was a takeaway. There is a contract in CBP that is a traveler vetting system contract that we won and these are the kinds of things that are providing us organic growth. And again, that's in the defense business.
If we want to think about in the Civil, organically, obviously, it's SD&A, but there is also some growth of existing programs that we're looking at for next year in the DOE, the NETL contract is one example. And then also -- so we have some expansion in our MSA contract there as well. So that -- those are the things that have been driving revenue growth. But probably also interesting is margin expansion that we're seeing both in those two businesses and really across the whole portfolio that has to do with really strong program performance and effective management of indirect costs as we kind of work through the pandemic, and these have been things that have more than offset some of the headwinds that we've had from COVID-19 and it really is a testament to the program teams and the management team that are out there driving those improvements.
Sheila Kahyaoglu -- Jefferies LLC -- Analyst
Okay. Thanks, Jim, for that. And then, one more for you, because we can't seemingly keep up with your puts and takes for free cash flow. So just to clarify on the -- because of the pre-funding of the $1 billion bond or the financing of that, how do we think about AR for this year? Is it net neutral? And how that flows over to 2021?
James Reagan -- Chief Financial Officer
Yeah. So for the full-year the impact of our AR monetization facility is going to be zero. Previously we had included in our guidance a $300 million add that shows up in operating cash flow, that is in effect the sale of our receivables at a very, very low cost of capital. And we don't need to do that now to maintain the level of liquidity that we want. We've got ample liquidity. So we don't need that anymore. So you can think about the $1.2 billion guide that we have today as being a $300 million improvement from a performance standpoint versus where we were last quarter.
Sheila Kahyaoglu -- Jefferies LLC -- Analyst
Okay. Great. Thank you.
James Reagan -- Chief Financial Officer
Thank you, Sheila.
Roger Krone -- Chairman and Chief Executive Officer
Great. Thanks, Sheila.
Operator
Our next question is from the line of Cai von Rumohr with Cowen. Please proceed with your questions.
Cai von Rumohr -- Cowen and Company -- Analyst
Yes. Thank you very much. Could you just refresh us in terms of the Defense, Health and the Army SOCOM protests, approximately how large were they? And when do you expect the protest timeline to be over?
Roger Krone -- Chairman and Chief Executive Officer
Okay, Cai, let me see if I can get these right. First of all, the total number we have in protest is about $9.3 billion. So if you add all the programs that we have collectively. The -- what we call RHRP program is rounded to $1 billion, give or take a little bit and it doesn't mean that's exactly what we'll book when we achieve the protest. And I think that's in January, right, is -- we don't get that till January.
And then the other program we refer to it as STAMP, which stands -- I'm -- of course, for something is about $600 million, $650 million. And then, of course, you add NextGen to that at about $8 billion, maybe a little less than that, $7.7 billion, $7.8 billion, and that gets you to about $9.3 billion. And I think the STAMP, we're hopeful will happen in the fourth quarter. So, if it doesn't get reprotested, which we're getting used to, but.
And then Navy NextGen, you didn't ask, I touched on it in my remarks. We're kind of -- whether it's before Thanksgiving or after Thanksgiving, it's hard to tell. You do oral arguments -- the Court of Federal Claims is not -- you can't set your clock by it, like you can with the GAO. And so, we'll go to oral arguments and then we are in the hands of the judge, and he can make a rule and any time after oral arguments from that day to probably a couple of weeks.
Cai von Rumohr -- Cowen and Company -- Analyst
Terrific. And then the second one would be your margins were good and you've talked about the COVID headwind. To what extent do you feel that COVID was a tailwind in terms of indirect expenses benefiting from lower travel and meeting expenses and utilization benefiting from lower paid vacation time off because there was fewer places for people to go?
Roger Krone -- Chairman and Chief Executive Officer
Yeah. Cai, that certainly -- was certainly a factor. Yeah. I don't know whether it's 20 bps or 30 bps, maybe something like -- I mean, it's a little hard to put our finger on it. The -- but clearly, made a difference. And our medical costs are down double-digit millions. And the challenge for all of us -- by the way, and it's all relatively good. The challenge I think for us and for the industry is to decide what comes back and what doesn't. We're at somewhere between 25% and 50% occupancy in our buildings and we're running just fine. We have 65% of our employees are telecommuting and they're doing reasonably well, I think, actually very well.
And we start to look at 2021 and say, we need less real estate. We don't need to go to all the trade shows that we've been to or at least not in person. Some of the virtual work that we've done on AUSA and AFA have worked actually extremely well. We've actually talked to more general officers, because you can Zoom them and you can do one right after another and they don't get caught in somebody else's show booth, right? So, we are really taking a look at the lessons learned and we want to capture and internalize significant portion of that reduction in our margin going forward. And I think you're seeing that across the board.
Cai von Rumohr -- Cowen and Company -- Analyst
Terrific. Thank you very much.
Roger Krone -- Chairman and Chief Executive Officer
Yeah.
James Reagan -- Chief Financial Officer
Thanks, Cai.
Operator
The next question is from the line of Jon Raviv with Citigroup. Please proceed with your questions.
Jonathan Raviv -- Citigroup -- Analyst
Hi, thank you. I was going to ask Sheila's question but Jim since you didn't fully hit through it, maybe I'll take another whack at it. It's just about big moving pieces into 2021, thanks for clarifying the AR this year. But thinking about 2021 over 2020 cash flow, are you sort of still looking at about $1 billion operating cash? I think that number has been thrown around previously? Or can we actually sustain at this $1.2 billion or greater going into 2021 with all those moving pieces, including I know payroll tax and whatnot? Thank you.
James Reagan -- Chief Financial Officer
Yeah. Jon, we'll have more to say about that when we issue our guidance at the end of the fourth quarter call. We were purposeful in not putting all the details out there because we're still working through that. I would tell you that this year has been benefited significantly by the ability to defer taxes into next year, and we'll have a lot of the moving parts for that available when we give you the kind of the walk of this year's cash flow to next year.
Another thing you have to remember is that, next year we're not going to have a repeat of VirnetX. That was $80 million. So, the strength of this year's cash conversion has really been on the backs of the CARES Act legislation, VirnetX, strong program performance and our continued focus on monetizing receivables, getting things build faster, getting them collected faster.
So, now, we always have these things that I referred to as recurring, non-recurrings, but we just -- we can't plan those. But who knows what next year's tailwind on cash flow might be. But like I said, we'll have more to say about that in next quarter's call.
Jonathan Raviv -- Citigroup -- Analyst
Yeah. I appreciate that. Thanks, Jim. And then just on your -- the incremental debt raise. Can you just clarify, how much are you actually taking out with that $1 billion or is it all just additional? And then you mentioned your capital priorities but with that additional debt, you're sort of looking, you mentioned some tuck-in the M&A capabilities. What are some of those opportunities that might be out there at this point size-wise and market-wise and capability-wise? Thank you.
James Reagan -- Chief Financial Officer
Yeah. I'll answer the first part of that question and Roger can speak to the second half about what we might be interested in. But the -- out of the $1 billion raise, we paid off debt to the tune of $750 million and we left $250 million in the cash account to give us the kind of flexibility that we're talking about. And then Roger can speak to the kinds of things that could represent tuck-ins with -- we don't have anything specific, but like I said, we want to have some flexibility and that's why we're keeping some cash around.
Roger Krone -- Chairman and Chief Executive Officer
Yeah. Jon, we're always working a pipeline of where do we want to be? What are the technologies that support the programs that we see three and five years out? And then we take a look internally within what we call our tactical core competencies and whether we're deep enough or not. And there tends to be kind of a make-buy decision and time to market. And there's -- yeah, at any given time, we'll have half a dozen $50 million to $250 million deals kind of in a pipeline and some are in diligence, some were just -- were wishful. And I don't really have anything to say at this time. Of course, we never comment on M&A anyway. But I don't think anything that's going to surprise you. I mean, if you've been listening to the call, as you know, where we're moving in digital transformation, hypersonics space, cyber, physical cyber, electronic warfare, that the whole list that we've been talking about for a long time. And there are some companies that have been in kind of PE or venture capital that are looking for liquidity event.
And by the way, one point I made before maybe interesting to remind everyone. Usually, the companies that we buy, we've had a relationship with for a long time. We do over and under, they might be a sub to us. We've probably been working with these companies for five years, some up to a decade. And we know the management team well. We know the technology well and especially the culture of the company. Culture is really a big thing for us and we want people that will fit with our organization. We're a little different because we're employee-owned for so long, which sort of a more of an open collaborative culture and culture is really big deal for us. But -- and if it doesn't work out, that we're happy to have them in a partnership relationship going forward. But that's kind of what we're looking at.
Jonathan Raviv -- Citigroup -- Analyst
Thank you.
Roger Krone -- Chairman and Chief Executive Officer
Yeah.
Operator
The next question is from the line of Rob Spingarn with Credit Suisse. Please proceed with your questions.
Robert Spingarn -- Credit Suisse -- Analyst
Hey. Good morning.
Roger Krone -- Chairman and Chief Executive Officer
Hey. Good morning, Rob.
Robert Spingarn -- Credit Suisse -- Analyst
I know you don't want to guide to next year, but you did mention that 10% to 12% and understanding that there are some moving pieces and delays and protests and so forth. Is there a way to talk about that qualitatively by segment?
James Reagan -- Chief Financial Officer
Well, Rob, we don't -- as we've said before, we don't guide by segment, right? But to speak to it qualitatively, it is -- it really is based on where we're kind of halfway through or near, maybe two-thirds of the way through planning for next year. And the early returns that are coming up from the units are consistent with kind of what the top down math looks like. Strong book-to-bill over the last 12 months, the contract lengths haven't gotten longer. We have some really big enterprise IT programs that are ramping. And with those, we could easily pencil out growth to the tune of what we said on -- earlier on the call.
But by segment, today, we're seeing expanding margins across each one of our segments and we think that next year could have some strong organic growth across the entire business because we're -- and we're pleased that across the portfolio, everything has strong book-to-bills and that translates to strong organic growth next year.
Roger Krone -- Chairman and Chief Executive Officer
Hey, Rob, let me jump on the back of that is, given our last two quarters and what happened in our Health business, and the amount of time we spent with the community on how the exam business works and we tried to be as transparent as we could is that, if we get to the point where the -- our clinics are shut down, we can't do exams. And so, we went through that period as, of course, everyone saw. But those, as we have said, and we said it on the last call, which is to repeat again, the exams don't go away. Those disability exams, whether Department of Labor or for the veterans or for Workman's Comp still have to get done. And so, we are now faced with sort of an inventory of exams. We have to work our way through.
And so, we're fortunate we ended the third quarter at higher than COVID levels, although for the quarter, we were probably kind of at or about where we were before starting lower, ending higher. But we now have to work through that inventory of exams and that's going to take us well into 2021 to do so. So, again, we tried to be transparent with everybody when we had to shut down the clinics, and what we'll look like when we were open. We're now reopened, all of our clinics are open. We still have PPE and we have to have appropriate protocols because the pandemic is currently alive and well out there. But we expect sort of the tailwind, certainly, from the exam business to go significantly into 2021.
Robert Spingarn -- Credit Suisse -- Analyst
Okay. Similar question, maybe higher level and looking at a little bit further, but with the potential changes in strategy, if we have a change in administration. Longer-term, Roger, how do we think about your service exposure changing in the Defense business? I'm talking about Army, Navy, Air Force exposure. Is that something you can speak about?
Roger Krone -- Chairman and Chief Executive Officer
Yeah. Well, I'll touch a little bit and then maybe if we have time at the end you can ask a second question. Yeah. And I get -- I always get wrapped up in when you use the word service, I want to stop and talk about the lower-end services is not the business that you'll find that Leidos is in, is that, we tend to be mission-focused. We don't do services. Right? We do solutions and we partner with our customers on mission.
But a comment, maybe we're leading to is like what will happen in the AOR in the Middle East, and Trump had made a commitment to pull troops down, and there have been troops. We have reduced our footprint in the Middle East. And I think we all anticipated that, that is likely to continue, I think, under either administration. The number is not going to go to zero. And part of what we do is, we provide support, not for the US troops but for the Afghans. Some of our aviation programs are in direct support of Afghan operations by Afganis. But we could see sort of a slowing down of some of the work that we do in theater, which frankly is a wonderful thing. It means we don't have troops at risk.
But the customers are going to take that obligation authority, and they're going to spend it in other areas. They may spend it in modernization, which is great for us because we are well positioned in the future of our customers. But what we have all learned is that, if it quiets down in Iraq and Afghanistan, it's going to get hot some place else. And unfortunately, history has told us is that, there is always a place to deploy troops.
And -- but I would tell you that we have been fortunate to suddenly shift our portfolio out of that very, very low-end and our OCO numbers are very small. And so, we are fairly well insulated to what I would call that pure services play, if that were to be de-emphasized in the budget.
Robert Spingarn -- Credit Suisse -- Analyst
Yeah. And what I was thinking about is just to -- just writ large if Army became a bill payer for growth at Air Force, Navy and in space, clearly, at Dynetics, you have very good exposure to all those growing thing. So that's the way I was thinking about it, that's certainly something that investors are asking us.
Roger Krone -- Chairman and Chief Executive Officer
Yeah. And again, we are -- why don't I let you go and we'll come back. I would simply say, we haven't seen it. Our support contracts to the Army is doing fine. I think there are some things around Army and strength and requires a longer conversation. I'd rather not use everybody else's time. But Rob, maybe we'll call you after the call and we can talk a little bit more about what we think is going on in the Army.
Robert Spingarn -- Credit Suisse -- Analyst
Okay.
Roger Krone -- Chairman and Chief Executive Officer
Thanks.
Operator
The next question is from the line of Peter Arment with Robert W. Baird. Please proceed with your questions.
Peter Arment -- Robert W. Baird & Co. Incorporated -- Analyst
Yeah. Thanks. Good morning, Roger and Jim. Roger, I just maybe just to talk briefly about kind of a follow on to Rob's question about 2021 just specifically when we think about the SD&A businesses. Just to clarify, do we -- is there an expectation that that visibility there in 2021 will actually -- we'll see a return to growth for that business? Or how should we be thinking about this -- the revenue profile of that business?
James Reagan -- Chief Financial Officer
It's a little early for us to know with specificity that part of what we call our security products business, which is actually being integrated in with the legacy Leidos business. I think that right now we're not viewing that as being a big grower for next year just because of what we think of is kind of the hangover from COVID-19. However, we can probably have more color on that in the next call as we have more visibility into how well the order pipeline has developed.
Peter Arment -- Robert W. Baird & Co. Incorporated -- Analyst
Okay. And just as a quick follow on, just regarding your ability in general to add new hires in this environment. How has that been proceeding? Thanks.
Roger Krone -- Chairman and Chief Executive Officer
It's been terrific. We went to a virtual hiring platform. We do virtual new employee orientation. We've got employees who are part of the Company are working from home who have never been to a Leidos building. And we're very, very fortunate that people see what's going on with the Company. They understand our culture. They love the work. They love working together and they love the workplace flexibility that we now offer. And so, hiring has not been a constraint for us.
Now, we were hoping that we would have had Navy NextGen in our portfolio by now, that is going to require a significant -- literally above a 1,000 people. And we hope that won't be our problem next year and we'll add that. And, of course, we've added a lot of people through the acquisitions, the Dynetics and the SD&A. All told, between direct hiring and the acquisitions, we'll probably add around 9,000 people this year.
Peter Arment -- Robert W. Baird & Co. Incorporated -- Analyst
Terrific. Thanks so much.
Roger Krone -- Chairman and Chief Executive Officer
Yeah.
Operator
Thank you. The next question is from the line of Gavin Parsons with Goldman Sachs. Please proceed with your questions.
Gavin Parsons -- Goldman Sachs -- Analyst
Hey. Good morning.
James Reagan -- Chief Financial Officer
Good morning, Gavin.
Roger Krone -- Chairman and Chief Executive Officer
Good morning, Gavin.
Gavin Parsons -- Goldman Sachs -- Analyst
Jim, just a quick one on the guidance assumptions. Last quarter you guys provided a pretty helpful slide on the sizing of COVID and the engine push out. I was wondering if you could just update us on the 2020 expected impact of COVID to revenue and EBITDA.
James Reagan -- Chief Financial Officer
We haven't provided anything specific. I can tell you that the change in the expectation on COVID-19 in 2020 is, the revenue impact is going to be a little bigger, but it isn't materially bigger and that the operating income impact on COVID-19 for the full-year is a little bit lower because of the recovery that we've seen in Q3 being a little bit faster than we had expected when we talked to you a quarter ago.
Gavin Parsons -- Goldman Sachs -- Analyst
Sorry, just to clarify, you are saying the revenue headwind is larger than you had been anticipating last quarter for all of this year?
James Reagan -- Chief Financial Officer
A little bit, and I wouldn't call it material. It's a small number.
Gavin Parsons -- Goldman Sachs -- Analyst
Got it. Okay. And then, Roger, the comment on visibility into growth was really helpful just on the authority and outlay is catching up to authority and the unobligated balance, your visibility in the backlog. But if I look at -- just kind of the May Investor Day, and the anticipation of a 5% addressable growth CAGR for your addressable markets. How do you think about planning differently given the political uncertainty and the budget deficit? And then whether or not you're still in a growth posture for a five-year outlook and then whether or not that changes how do you plan for the business? Thanks.
Roger Krone -- Chairman and Chief Executive Officer
Yeah. Okay. I'll try to be short because I know we're running late. But, first of all, you raised the unobligated balance, by our numbers, it's $130 billion. So there is a ton of budget overhang of, if you will, unspent prior authorized balances. So, add that to the CR and you see your way through 2021 and 2022. And clearly, in our Investor Day, we were talking 5%. We're kind of -- our conversation now begins at 10% and it goes north from there.
We run the same scenario as everybody else does, what is the federal deficit? What's it take to get to a balanced budget? And those numbers are in such large magnitude. I mean, you could remove the NASA budget completely, and you don't even make a dent. So, we have some longer structural things as a country that we need to better understand and there are some inflation that has to happen and so you can pay debt off 10 years with inflated dollars and things.
But what we have heard talking to both administrations and the Hill is, we need economic growth, that's what's going to get us back on firm footing. And you can't make huge reductions in the -- in federal spending and get the economic recovery that you need over the next three to five years. So, we may see a little bit of topline temperament. But I think the big change that we're going to see is, if Biden were to get elected versus Trump, a reprioritization of what is a Federal Government budget that grows kind of with GMP [Phonetic]. So you're talking 2.7%, 2.8%, maybe 3% GMP growth.
And if you plot history, President-to-President, the Federal Government spending is pretty constant. What changes is priorities within the two administrations or within different administrations. And we think we've done a really good job of portfolioing [Phonetic] this Company so that we can shift to more health and infrastructure, if a Biden government were to go in that direction.
And we've talked a line -- I don't want to go on too much, but the -- I don't think you solve the deficit problem with spending. I think you're going to have to find sources of revenue. And everybody says, oh that means, taxes and we said, yeah, probably eventually we could see the corporate rate start to creep back to where it was. But other sources of revenue like users' fees at [Phonetic] parks and things like that, it's just what's going to have to happen. It's going to take some smarter people then I to figure out how we pay off these trillions and trillions of dollars that we've borrowed to keep people employed. So -- but with that, I think we -- again, we got to wrap it up, but we can follow up with you on the one on one.
Gavin Parsons -- Goldman Sachs -- Analyst
Thanks.
Operator
Thank you. At this time, I'll turn the floor back to management for closing comments.
Peter M. Berl -- Head of Investor Relations
Hey. Thanks, Rob. Thank you all for your time this morning and for your interest in Leidos. We look forward to updating you again soon. Have a great day.
Operator
[Operator Closing Remarks]
Duration: 65 minutes
Call participants:
Peter M. Berl -- Head of Investor Relations
Roger Krone -- Chairman and Chief Executive Officer
James Reagan -- Chief Financial Officer
Joseph DeNardi -- Stifel Financial Corp. -- Analyst
Seth Seifman -- J.P. Morgan -- Analyst
Matthew Akers -- Barclays -- Analyst
Sheila Kahyaoglu -- Jefferies LLC -- Analyst
Cai von Rumohr -- Cowen and Company -- Analyst
Jonathan Raviv -- Citigroup -- Analyst
Robert Spingarn -- Credit Suisse -- Analyst
Peter Arment -- Robert W. Baird & Co. Incorporated -- Analyst
Gavin Parsons -- Goldman Sachs -- Analyst
